References

1. Malhotra B. Dermatofibrosarcoma protuberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Curr Opin Oncol. 2012 Jul;24(4):419-24. Google Scholar


2. Pachet C. Apport de la chirurgie micrographique dans la réduction des marges du dermatofibrosarcome de Darier et Ferrand: étude de 31 cas comparant l'exérèse large et la chirurgie micrographique et revue de la littérature. Mémoire DES de chirurgie générale, université Paris-VII-Denis-Diderot. 2007.


3. Lemm D et al. Current treatment options in dermatofibrosarcoma protuberans. Cancer Res Clin Oncol. 2009 ;135(5): 653-65. PubMed | Google Scholar


4. Foroozan M, Sei JF, Amini M et al. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148(9): 1055-63. PubMed | Google Scholar


5. Farma JM, Ammori JS, Zager JS et al. Dermatofibrosarcoma protuberans: how wide should we respect. Ann Surg Oncol. 2010; 17: 2112-8. Google Scholar


6. Shimizu S. The DFS platelet derived growth factor B-chain fusion gene. Cancer Res. 1999 Aug 1;59(15):3719-23.


7. Pagès C et al. Thérapies ciblées et dermatofibrosarcome de Darier et Ferrand. Oncologie. 2013;15: 97-100. Google Scholar


8. Greco A, Roccato E, Miranda C et al. Growth-inhibitory effect of STI 571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 2001 May 1; 92(3):354-60. Google Scholar


9. McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol. 2005 Feb 1;23(4):866-73. PubMed


10. Dufresne A et al. Biologie moléculaire des sarcomes et choix thérapeutiques molecular biology of sarcoma and therapeutic choices. Bulletin du Cancer. January 2015;102(1):6-16. Google Scholar